Investing in Healthcare Innovation

At MPM, we focus equally on capturing and creating value. We capture value by identifying under-appreciated assets and by understanding risk. We "create" value by doing whatever it takes to help our companies succeed.

NVCA Member 2008-2009

Latest News

Jul 21, 2010 BV 4 Portfolio Company Alnara Pharmaceuticals: Lilly Announces Completion of Acquisition

Jul 08, 2010 BV 4 Portfolio Company iPierian Closes $22 Million Series B Financing Led By Google Ventures

Jul 06, 2010 BV 2 Portfolio Company SenoRx Completes Sale to C. R. Bard

Jul 02, 2010 BV 4 Portfolio Company Alnara Pharmaceuticals to be Acquired by Lilly

Jun 28, 2010 BV 4 Portfolio Company Chiasma Receives Orphan Drug Designation From The FDA